Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis – a review of population-specific evidence from randomized clinical trials
Antonios Bayas, Monika Christ, Simon Faissner, et al.
Therapeutic Advances in Neurological Disorders (2023) Vol. 16
Open Access | Times Cited: 17

Showing 17 citing articles:

Challenges in Diagnosis and Therapeutic Strategies in Late-Onset Multiple Sclerosis
Viviana Nociti, Marina Romozzi, Massimiliano Mirabella
Journal of Personalized Medicine (2024) Vol. 14, Iss. 4, pp. 400-400
Open Access | Times Cited: 5
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
Martin Vališ, Anat Achiron, Hans Hartung, et al.
Drugs in R&D (2023) Vol. 23, Iss. 4, pp. 331-338
Open Access | Times Cited: 12
A future of AI-driven personalized care for people with multiple sclerosis
Jelle Praet, Lina Anderhalten, Cristoforo Comi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA)
Clara Grazia Chisari, Maria Pia Amato, Alessia Di Sapio, et al.
Journal of Neurology (2024) Vol. 271, Iss. 10, pp. 6801-6810
Open Access | Times Cited: 2
Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation
Uwe K. Zettl, Paulus Rommer, Orhan Aktaş, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 11, pp. 1343-1359
Open Access | Times Cited: 6
Combined analysis of bulk and single-cell RNA sequencing reveals novel natural killer cell-related prognostic biomarkers for predicting immunotherapeutic response in hepatocellular carcinoma
Kai Zhang, Enwu Yuan
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project
Damiano Paolicelli, Giovanna Borriello, Raffaella Clerici, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 5, pp. 1415-1430
Open Access | Times Cited: 1
The Faces of “Too Late”—A Surprisingly Progressive Cohort of “Stable” Relapsing Remitting Multiple Sclerosis Patients
Alin Ciubotaru, Cristina Grosu, Daniel Alexa, et al.
Medicina (2024) Vol. 60, Iss. 9, pp. 1401-1401
Open Access | Times Cited: 1
Prospects of treatment of progressive forms of multiple sclerosis by transplantation of stem cells (review)
T. V. Sorokovikova, А. М. Morozov, A. N. Kryukova, et al.
Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH) (2023) Vol. 13, Iss. 4, pp. 154-161
Open Access | Times Cited: 2
Development Perspectives for Curative Technologies in Primary Demyelinating Disorders of the Central Nervous System with Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) at the Forefront
János G. Pitter, László Nagy, Balázs Vince Nagy, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 6, pp. 599-599
Open Access
Numerical modelling of multiple sclerosis: A tissue-scale model of brain lesions
H. E. Hutchison, AC Szekely-Kohn, William Li, et al.
Brain Multiphysics (2024) Vol. 7, pp. 100097-100097
Open Access
Markers of Secondary Progression in Multiple Sclerosis
André Pessoa Silva de Bastos, Mafalda Soares, Joana Guimarães
Multiple Sclerosis and Related Disorders (2024) Vol. 91, pp. 105881-105881
Open Access
Impact of Siponimod on Clinical and Radiological Parameters of Secondary Progressive Multiple Sclerosis: A Real-World Prospective Study
Konstantina Stavrogianni, Dimitrios K. Kitsos, Vasileios Giannopapas, et al.
Journal of Clinical Neurology (2024) Vol. 20, Iss. 6, pp. 591-591
Open Access
Anhalten der Behinderungsprogression unter Siponimod bei sekundär chronisch progredienter Multipler Sklerose
Iason Bartzokis
Nervenheilkunde (2024) Vol. 43, Iss. 11, pp. 642-644
Closed Access
Role of Epstein-Barr Virus in Multiple Sclerosis
A. Donaldson, William A. Frazier, Steven Jacobson
NeuroImmune Pharmacology and Therapeutics (2024), pp. 445-460
Closed Access
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry
Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Journal of Neurology (2023) Vol. 271, Iss. 3, pp. 1150-1159
Closed Access | Times Cited: 1
Investigating the Mitoprotective Effects of S1P Receptor Modulators Ex Vivo Using a Novel Semi-Automated Live Imaging Set-Up
Rebecca Ludwig, Bimala Malla, Maria Höhrhan, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 261-261
Open Access | Times Cited: 1
Page 1

Scroll to top